PolyTherics to collaborate with UCL to develop a new treatment for ‘sticky blood’ syndrome

29-Sep-2010 - United Kingdom

PolyTherics Limited announced a new collaboration with Professor Anisur Rahman at UCL (University College London), to use its proprietary site-specific PEGylation to develop a treatment for antiphospholipid syndrome. Professor Rahman and his team have been awarded a 5-year grant of nearly £700,000 from arthritis Research UK to support the work.

Antiphospholipid syndrome (APS), also known as ‘sticky blood’ syndrome, is an autoimmune disease that particularly affects young people and causes blood clots, strokes or recurrent miscarriages. It occurs more commonly in patients with autoimmune rheumatic diseases such as systemic lupus erythematosus. Patients with APS have antibodies to their own phospholipid which bind to phospholipid-protein complexes in the body. This is thought to trigger changes that affect blood clotting. There is no cure for APS; patients are sometimes given anti-coagulant drugs to prevent blood clots but these can have serious side effects.

Professor Rahman and the UCL team have developed proteins that block the binding of anti-phospholipid antibodies to phospholipid-protein complexes in the bloodstream. The next step is to improve the characteristics of these proteins so that they circulate in the body for longer whilst retaining their ability to block this binding. PolyTherics’ proprietary site-specific PEGylation technology is designed to achieve this and its scientists will work closely with the UCL team to produce PEGylated versions of the proteins, which will then be tested by Professor Rahman’s group.

Other news from the department science

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Last viewed contents

A taste for plastic - Discovered for the first time: New deep-sea enzyme breaks down PET plastic

A taste for plastic - Discovered for the first time: New deep-sea enzyme breaks down PET plastic

From smoky skies to a green horizon: Scientists convert fire-risk wood waste into biofuel - A simplified new process transforms wood waste from agriculture and forest management into ethanol

From smoky skies to a green horizon: Scientists convert fire-risk wood waste into biofuel - A simplified new process transforms wood waste from agriculture and forest management into ethanol

Generex Awarded New Patent in Morocco

Images of antibodies working together against malaria

Images of antibodies working together against malaria

Chemie.DE Information Service's 10th Anniversary: an Online Success Story

Chemie.DE Information Service's 10th Anniversary: an Online Success Story

Evocatal GmbH Closes New Financing Round

Eppendorf opens new site in Singapore - Targeted strengthening of customer focus with high-tech laboratory for pipette calibration
and extensive range of high-quality laboratory services

Eppendorf opens new site in Singapore - Targeted strengthening of customer focus with high-tech laboratory for pipette calibration and extensive range of high-quality laboratory services

Evotec enters partnership with Vienna start-up - Quantro exploits innovative functional-genetic and transcriptomic technologies to address “undruggable” targets

Evotec enters partnership with Vienna start-up - Quantro exploits innovative functional-genetic and transcriptomic technologies to address “undruggable” targets

BluCon Biotech and LG Chem enter into unique investment agreement - BluCon Biotech's technology has the potential to be a disruptive game changer in the world's plastics market

BluCon Biotech and LG Chem enter into unique investment agreement - BluCon Biotech's technology has the potential to be a disruptive game changer in the world's plastics market

Antibiotic ribosomal compounds deciphered - Combating multidrug-resistant bacteria through high-resolution structural imaging

Antibiotic ribosomal compounds deciphered - Combating multidrug-resistant bacteria through high-resolution structural imaging

Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement - Single-Molecule DNA Sequencing System Promises Dramatic Improvement in Cost, Speed, Versatility, and Simplicity of Sequencing

CT Atlantic AG Announces Appointment of Michael Höcker to CEO - Cara Lerner joins CT Atlantic as COO